Influenza
1,371
54
85
1,109
Key Insights
Highlights
Success Rate
96% trial completion (above average)
Published Results
460 trials with published results (34%)
Research Maturity
1109 completed trials (81% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
3.1%
42 terminated out of 1371 trials
96.4%
+9.8% vs benchmark
36%
495 trials in Phase 3/4
41%
460 of 1109 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1109 completed trials
Clinical Trials (1371)
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.
Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)
A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
Virological Surveillance of Acute Respiratory Infection in Primary Health Care in Metropolitan France
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP
The Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)
Taxifolin/Ergothioneine and Immune Biomarkers in Healthy Volunteers (TaxEr)
Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine
First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics
InFLUenza and the HEART An Investigation Into the Acute and Lasting Cardiac Effects of Influenza Infection
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts